Literature DB >> 5578233

Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum.

W M Newberry, J P Sanford.   

Abstract

In defining host resistance factors in uremia, experiments were designed to assess the effect of renal failure serum upon the reactivity of normal human lymphocytes to phytohemagglutinin in vitro. Normal buffy coat cells were resuspended in sera obtained from normal subjects and from 14 patients with renal failure, then stimulated with phytohemagglutinin M and the cellular response measured by the increase in thymidine or uridine uptake. The mean thymidine uptake by stimulated cells in normal sera was 14,389 +/-1695 (SEM) cpm per 2 x 10(6) lymphocytes. Uridine uptake under the same conditions was 12,540 +/-1887 cpm. Compared to these are a mean thymidine uptake of 2740 +/-457 cpm and uridine uptake of 3928 +/-667 cpm in renal failure sera. Both differences are significant at P<0.01 level. For controls representing "chronic illnesses," sera from patients with pneumococcal meningitis, cirrhosis of the liver without jaundice, rheumatoid arthritis, and paraplegia with urinary tract infection did not cause suppression. No single drug had been taken by all the renal failure patients; three patients were taking no drugs. The serum from one patient with acute renal failure suppressed thymidine uptake while her serum obtained after recovery from her illness supported a normal lymphocyte response. Improvement of lymphocyte response was also noted in 9 of 10 sera obtained from patients immediately after hemodialysis. These observations plus the inhibition of stimulated cells by normal serum mixed with renal failure serum indicate the presence of a dialyzable inhibitory factor rather than the absence of a supporting factor in the renal failure sera. Lymphocytes preincubated for 24 hr in renal failure serum responded normally when transferred to normal serum and stimulated. Cells stimulated in normal serum and transferred to renal failure serum within the initial 24 hr of incubation demonstrated depressed thymidine uptake. Also, cell survival for 72 hr incubation as judged by trypan blue exclusion and chromium-51 release was similar in normal and renal failure sera. Thus, the suppressive effect of renal failure serum does not depend upon the initial phytohemagglutinin-cell interaction nor upon a significant cytotoxic effect. These studies demonstrate that a dialyzable factor(s) in the serum of patients with renal failure can greatly suppress one parameter by which an immune function of circulating lymphocytes is assessed and provides at least, a partial explanation for delayed homograft rejections in renal failure as well as the susceptibility of such patients to various infections.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5578233      PMCID: PMC292056          DOI: 10.1172/JCI106604

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Observations on the surgical care of patients with posttraumatic renal insufficiency.

Authors:  H H BALCH; W H MERONEY; Y SAKO
Journal:  Surg Gynecol Obstet       Date:  1955-04

2.  Evidence that methylguanidine is retained in chronic renal failure.

Authors:  S Giovannetti; M Biagini; L Cioni
Journal:  Experientia       Date:  1968-04-15

3.  Chronic pulmonary disease and immunologic deficiency.

Authors:  C H Kirkpatrick; W E Ruth
Journal:  Am J Med       Date:  1966-09       Impact factor: 4.965

4.  Guanidinosuccinic acid in renal failure, experimental azotemia and inborn errors of the urea cycle.

Authors:  I M Stein; B D Cohen; R S Kornhauser
Journal:  N Engl J Med       Date:  1969-04-24       Impact factor: 91.245

5.  In vitro reactivity of human lymphocytes in uraemia--a comparison with the impairment of delayed hypersensitivity.

Authors:  H Huber; D Pastner; P Dittrich; H Braunsteiner
Journal:  Clin Exp Immunol       Date:  1969-07       Impact factor: 4.330

6.  Defective ADP-induced platelet factor 3 activation in uremia.

Authors:  H I Horowitz; B D Cohen; P Martinez; M F Papayoanou
Journal:  Blood       Date:  1967-09       Impact factor: 22.113

7.  Application of the 51Cr cytotoxicity technique to the analysis of human lymphocyte isoantigens.

Authors:  G N Rogentine; B A Plocinik
Journal:  Transplantation       Date:  1967-09-05       Impact factor: 4.939

8.  The effect of uremic plasma on lymphocyte transformation.

Authors:  M R Silk
Journal:  Invest Urol       Date:  1967-09

9.  Cellular evolution in induced inflammation in uremic patients.

Authors:  P A Lang; S E Ritzmann; F L Merian; M C Lawrence; W C Levin; R Gregory
Journal:  Tex Rep Biol Med       Date:  1966

10.  Local immune response in experimental pyelonephritis.

Authors:  J D Lehmann; J W Smith; T E Miller; J A Barnett; J P Sanford
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

View more
  42 in total

1.  Increased expression of CD25 and HLA-DR on lymphocytes recruited into the peritoneal cavity in non-infected CAPD patients.

Authors:  A Brauner; B Hylander; S H Jacobson; A Moshfegh; J Lundahl
Journal:  Inflammation       Date:  2001-12       Impact factor: 4.092

2.  In vitro reactivity of lymphocytes obtained from uraemic patients maintained by heamodialysis.

Authors:  D P Sengar; A Rashid; J E Harris
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

3.  [Effect of higher molecular urine metabolites on lymphocyte transformation and autohemolysis (author's transl)].

Authors:  R Korz; A Naber; H Brunner; U Buschsieweke; U Essers
Journal:  Klin Wochenschr       Date:  1975-08-15

4.  Thymus lymphocytes in uraemic rats and the effect of thymosin fraction 5 in vitro.

Authors:  S Ikemoto; T Kishimoto; S Wada; N Hayahara; M Maekawa
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

5.  Humoral inhibitors of the immune response in uremia. II. Further characterization of an immunosuppressive factor in uremic serum.

Authors:  J Raskova; A B Morrison; S M Shea; K Raska
Journal:  Am J Pathol       Date:  1979-11       Impact factor: 4.307

Review 6.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 7.  Cell-mediated immunity and its role in resistance to infection.

Authors:  E J Wing; J S Remington
Journal:  West J Med       Date:  1977-01

8.  Immune defects in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on haemodialysis.

Authors:  N D Tsakolos; T C Theoharides; E D Hendler; J Goffinet; J M Dwyer; R L Whisler; P W Askenase
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

9.  Cancer and chronic renal failure.

Authors:  G Digenis; A Pierratos; D G Oreopoulos
Journal:  CMAJ       Date:  1986-07-01       Impact factor: 8.262

10.  Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components.

Authors:  K Kamata; M Okubo; M Sada
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.